Skip to main content

HepaREF

Benchmark. Normalize. Translate

A fully characterized human liver proteome reference standard for LC-MS proteomics-built to benchmark datasets, compare liver models, and improve confidence in translational research.

Request an evaluation sampleSee what is included

One reference. More comparable results.

Use HepaREF as a consistent human-liver benchmark across experiments, models, instruments, laboratories, and sites.

Characterized human liver proteome

Quantified Phase I/II enzymes, transporters, and key biomarkers.

Population-level context

Reference data helps place results within human population-level proteomic distributions.

Workflow-ready material

Compatible with LC-MS workflows and available as digested and undigested reagents.

A DEFINED QUANTITATIVE BENCHMARK

Anchor results in human liver biology

HepaREF provides characterized abundance data for important drug-metabolizing enzymes and transporters- giving teams a common point of comparison.

✓ Benchmark datasets and monitor analytical
performance

✓ Normalize across laboratories and multi-site studies

Compare hepatocyte lots and advanced liver models

Support IVIVE and PBPK model development

Where HepaREF fits

Designed for teams developing, evaluating, or translating human liver models and proteomic methods.

Validate and qualify in vitro liver models and NAMs

Improve IVIVE predictions and PBPK modeling

Standardize datasets across multi-site studies

Quantify enzymes, transporters, and relevant biomarkers

Support method development and performance monitoring

Study interindividual variability with human context

What You Receive with HepaREF

• HepaREF reference material

• Associated quantitative characterization data

• Certificate or supporting documentation

• Guidance for interpretation and use

• Access to PQ scientific support

See how HepaREF performs in your workflow.

Request an evaluation sample or speak with a Precision Quantomics scientist

Contact us

For research use only. Product specifications and claims should be confirmed before publication.